Rome, Italy

Gian Piero Moretti


Average Co-Inventor Count = 3.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2001-2006

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Gian Piero Moretti: Innovator in Pharmaceutical Chemistry

Introduction

Gian Piero Moretti is a distinguished inventor based in Rome, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with therapeutic applications. With a total of 4 patents to his name, Moretti's work has the potential to impact various medical treatments.

Latest Patents

Among his latest patents, Moretti has developed bis-heterocyclic compounds that exhibit antitumour and chemosensitising activity. These compounds are described by a general formula and are useful as agents in cancer treatment. Additionally, he has patented 2-aminotetralines along with pharmaceutical compositions aimed at preventing and therapeutically treating inflammatory and autoimmune pathologies. This includes a focus on conditions such as septic shock, where inflammatory cytokines play a critical role.

Career Highlights

Gian Piero Moretti is currently associated with Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., a company known for its commitment to pharmaceutical innovation. His work at Sigma-Tau has allowed him to explore and develop new therapeutic agents that address significant health challenges.

Collaborations

Moretti has collaborated with notable colleagues in his field, including Piero Foresta and Nicola Fanto'. These partnerships have fostered a collaborative environment that enhances the research and development of innovative pharmaceutical solutions.

Conclusion

Gian Piero Moretti's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…